Advertisement
UK markets closed
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • CRUDE OIL

    83.04
    +0.35 (+0.42%)
     
  • GOLD FUTURES

    2,399.10
    +10.70 (+0.45%)
     
  • DOW

    37,748.85
    -4.46 (-0.01%)
     
  • Bitcoin GBP

    50,850.63
    +2,092.05 (+4.29%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,637.15
    -46.22 (-0.29%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...